PE20010025A1 - Uso de un inhibidor de fpt y un inhibidor de la via de senalizacion ras adicional para inducir la muerte de celulas cancerosas y la regresion de tumores - Google Patents

Uso de un inhibidor de fpt y un inhibidor de la via de senalizacion ras adicional para inducir la muerte de celulas cancerosas y la regresion de tumores

Info

Publication number
PE20010025A1
PE20010025A1 PE2000000317A PE0003172000A PE20010025A1 PE 20010025 A1 PE20010025 A1 PE 20010025A1 PE 2000000317 A PE2000000317 A PE 2000000317A PE 0003172000 A PE0003172000 A PE 0003172000A PE 20010025 A1 PE20010025 A1 PE 20010025A1
Authority
PE
Peru
Prior art keywords
inhibitor
day
growth factor
receptor
ras signaling
Prior art date
Application number
PE2000000317A
Other languages
English (en)
Inventor
Walter R Bishop
Diana L Brassard
Tattanahalli L Nagabhushan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20010025A1 publication Critical patent/PE20010025A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE AL USO DE a)UN INHIBIDOR DE FARNESIL TRANSFERASA FPT TAL COMO BENZOCICLOHEPTAPIRIDINA TRICICLICA DE ANILLO FUSIONADO DE FORMULA I, UTILIZANDOSE 1,4 mg/DIA A 400 mg/DIA; b)UN INHIBIDOR DE LA VIA DE SENALIZACION RAS ADICIONAL TAL COMO UN INHIBIDOR DE QUINASA, UN INHIBIDOR DE LA PROTEINA MEK, UN INHIBIDOR DEL RECEPTOR DEL FACTOR DE CRECIMIENTO (UN INHIBIDOR DE TIROSINQUINASA COMO UN INHIBIDOR DEL RECEPTOR erbB2; UN INHIBIDOR DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DERIVADO DE PLAQUETAS PDGF; UN INHIBIDOR DEL RECEPTOR IGF, UN INHIBIDOR DE TIROSINQUINASA DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO EGF, ANTICUERPO DIRIGIDO CONTRA EL ANTICUERPO DIRIGIDO CONTRA EL DOMINIO EXTRACELULAR DE UN RECEPTOR DEL FACTOR DE CRECIMIENTO); UTILIZANDOSE UNA CANTIDAD DE 1 mg/DIA A 350 mg/DIA, SE ADMINISTRAN SIMULTANEAMENTE O EN SECUENCIA; c)UN AGENTE QUIMIOTERAPEUTICO TAL COMO CLORMETINA, CICLOFOSFAMIDA, IFOSFAMIDA, MELFALAN, CLORAMBUCIL, PIPOBROMAN, TRIETILEN-MELAMINA, TRIETILENOFOSFORAMINA, BUSULFAN, CARMUSTINA, LOMUSTINA, STREPTOZOCINA, DACARBAZINA, TEMOZOLOMIDA, ANTIMETABOLITOS, METOTREXATO, 5-FLUORURACILO, FLOXURIDINA, CITARABINA, 6-MERCAPTOPURINA, ENTRE OTROS; d)RADIACION. LA COMBINACION PRODUCE UN NIVEL SINERGICO PARA PRODUCIR LA MUERTE DE LAS CELULAS CANCEROSAS UTIL PARA EL TRATAMIENTO DE CANCER DE PULMON, CANCER PANCREATICO
PE2000000317A 1999-04-09 2000-04-07 Uso de un inhibidor de fpt y un inhibidor de la via de senalizacion ras adicional para inducir la muerte de celulas cancerosas y la regresion de tumores PE20010025A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/289,255 US6316462B1 (en) 1999-04-09 1999-04-09 Methods of inducing cancer cell death and tumor regression

Publications (1)

Publication Number Publication Date
PE20010025A1 true PE20010025A1 (es) 2001-02-05

Family

ID=23110723

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000317A PE20010025A1 (es) 1999-04-09 2000-04-07 Uso de un inhibidor de fpt y un inhibidor de la via de senalizacion ras adicional para inducir la muerte de celulas cancerosas y la regresion de tumores

Country Status (24)

Country Link
US (1) US6316462B1 (es)
EP (1) EP1165078B1 (es)
JP (1) JP2003529540A (es)
CN (1) CN100421661C (es)
AR (1) AR023400A1 (es)
AT (1) ATE347360T1 (es)
AU (1) AU783177B2 (es)
BR (1) BR0009670A (es)
CA (1) CA2364675A1 (es)
CY (1) CY1107545T1 (es)
DE (1) DE60032226T2 (es)
DK (1) DK1165078T3 (es)
ES (1) ES2275505T3 (es)
HK (1) HK1038512B (es)
HU (1) HUP0200773A3 (es)
MX (1) MXPA01010211A (es)
MY (1) MY120841A (es)
NO (1) NO329133B1 (es)
NZ (1) NZ514628A (es)
PE (1) PE20010025A1 (es)
PT (1) PT1165078E (es)
TW (1) TWI255184B (es)
WO (1) WO2000061145A1 (es)
ZA (1) ZA200108258B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
WO2001000245A2 (en) * 1999-06-25 2001-01-04 Genentech, Inc. HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
CA2397657A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Farnesyl protein transferase inhibitor combinations with platinum compounds
DE10017480A1 (de) * 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
AU2001259271A1 (en) * 2000-04-28 2001-11-12 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
US20020064785A1 (en) 2000-05-19 2002-05-30 Genentech Inc. Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
NZ524936A (en) * 2000-10-05 2005-08-26 George Q Methods of inducing cancer cell death and tumor regression using a FTP inhibitor and a tyrosine kinase inhibitor
EP1353693B1 (en) 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
JP4358510B2 (ja) 2001-01-18 2009-11-04 シェーリング コーポレイション テモゾロミドおよびアナログの合成
NZ516873A (en) * 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
US6703400B2 (en) 2001-02-23 2004-03-09 Schering Corporation Methods for treating multidrug resistance
AU2002352941A1 (en) * 2001-11-30 2003-06-17 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
WO2003047586A1 (en) * 2001-12-03 2003-06-12 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
IL164799A0 (en) 2002-04-25 2005-12-18 Univ Connecticut Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US6984389B2 (en) * 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
CA2484000A1 (en) * 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
AU2003287366A1 (en) * 2002-10-31 2004-06-07 University Of Rochester Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US8168568B1 (en) 2003-03-10 2012-05-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Combinatorial therapy for protein signaling diseases
EP2365001A3 (en) * 2003-05-01 2012-03-28 Imclone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
JP2007511203A (ja) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
SI1663978T1 (sl) 2003-07-23 2008-02-29 Bayer Pharmaceuticals Corp Fluoro substituirana omega-karboksiaril difenil secnina za zdravljenje ali preprecevanje bolezni instanj
JP2007510434A (ja) 2003-11-12 2007-04-26 シェーリング　コーポレイション 多重遺伝子発現のためのプラスミドシステム
CA2546727C (en) 2003-11-20 2012-10-02 Children's Hospital Medical Center Gtpase inhibitors and methods of use
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
AU2005209909B8 (en) * 2004-02-03 2009-01-15 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
MX2007006640A (es) * 2004-12-03 2007-06-19 Schering Corp Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
UA94899C2 (ru) 2005-01-21 2011-06-25 Дженентек, Инк. Фиксированное дозирование антител к her
RS53128B (en) 2005-02-23 2014-06-30 Genentech Inc. Extending the time of disease progression or survival in patients with ovarian cancers using PERTUZUMAB
US7524831B2 (en) * 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
EP1879587A2 (en) * 2005-04-15 2008-01-23 Schering Corporation Methods and compositions for treating or preventing cancer
EP2439273B1 (en) * 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US20060286103A1 (en) * 2005-06-15 2006-12-21 Parag Kolhe Stable antibody formulation
ES2452115T3 (es) * 2005-06-17 2014-03-31 Imclone Llc Un anticuerpo anti-PDGFRalfa para su uso en el tratamiento de cáncer de huesos metastásico
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US9095581B2 (en) 2005-07-21 2015-08-04 Ardea Biosciences, Inc. Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof
AU2006275528B2 (en) 2005-07-29 2012-03-08 Children's Hospital Medical Center GTPase inhibitors and methods of use and crystal structure of Rac-1 GTPase
AP2008004569A0 (en) * 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
EP2405270B1 (en) * 2006-06-30 2013-07-17 Merck Sharp & Dohme Corp. IGFBP2-Biomarker
CA2667362A1 (en) * 2006-10-25 2008-05-02 Schering Corporation Methods of treating ovarian cancer
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
MX2009012054A (es) 2007-05-08 2009-11-19 Schering Corp Metodos de tratamiento que usan formulaciones intravenosas que comprenden temozolomida.
DK2171090T3 (da) 2007-06-08 2013-06-10 Genentech Inc Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA2694646C (en) * 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
US20110129549A1 (en) * 2008-04-17 2011-06-02 Liu Julie F Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US20100056555A1 (en) * 2008-08-29 2010-03-04 Enzon Pharmaceuticals, Inc. Method of treating ras associated cancer
KR20110075029A (ko) * 2008-10-21 2011-07-05 엔즌 파마슈티칼스, 인코포레이티드 7-에틸-10-하이드록시캄토테신의 다중-암 고분자 컨쥬게이트로 신경모세포종의 치료
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
MY160556A (en) 2010-02-18 2017-03-15 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
KR20140098834A (ko) 2011-11-30 2014-08-08 제넨테크, 인크. 암에서의 erbb3 돌연변이
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
US11331312B2 (en) * 2014-04-25 2022-05-17 Memorial Sloan-Kettering Cancer Center Treatment of H-Ras-driven tumors
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
US20240058321A1 (en) 2021-11-02 2024-02-22 Semmelweis Egyetem Farnesyl-transferase inhibitors and kras inhibitors for treating kras mutant cancers

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2546577B2 (de) 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
EP0214092A1 (en) 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0341860B1 (en) 1988-04-28 1994-07-13 Schering Corporation Benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use
US5393890A (en) 1988-06-02 1995-02-28 Ajinomoto Co., Inc. Piperidine derivatives and hypotensives containing the same
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
JPH06504772A (ja) * 1990-12-18 1994-06-02 ザ　ウエルカム　ファウンデーション　リミテッド 抗癌剤の薬効を増強し抗多剤耐性を有する薬剤
ATE153336T1 (de) 1992-03-27 1997-06-15 Schering Corp Verbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung
US5512293A (en) 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
FR2698560B1 (fr) 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
TW308594B (es) 1993-10-15 1997-06-21 Schering Corp
US5719148A (en) 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5661152A (en) 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5464840A (en) 1993-12-06 1995-11-07 Schering Corporation Tricyclic derivatives, compositions and methods of use
US5523095A (en) 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
TW406022B (en) 1994-12-19 2000-09-21 Daiichi Seiyaku Co Method for producing slow-release granular agents
US5700806A (en) 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5684013A (en) 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6083985A (en) 1995-08-09 2000-07-04 Banyu Pharmaceutical Co., Ltd. Medicinal composition
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
TW350844B (en) * 1995-12-22 1999-01-21 Schering Corp Tricyclic amides useful to inhibition of G-protein function and for treatment of proliferative diseases
CA2250232A1 (en) 1996-04-03 1997-10-09 Allen I. Oliff A method of treating cancer
CA2251716A1 (en) 1996-04-15 1997-10-23 W. Gillies Mckenna Sensitization of cells to radiation and chemotherapy
JP2000513711A (ja) 1996-04-18 2000-10-17 メルク エンド カンパニー インコーポレーテッド 癌の治療法
EP0934270A1 (en) 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
ES2224256T3 (es) 1996-06-28 2005-03-01 Schering Corporation Disolucion solida de un agente antifungico con biodisponibilidad mejorada.
US5985879A (en) 1996-09-13 1999-11-16 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6071907A (en) 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US6040305A (en) 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
ID21577A (id) 1996-09-13 1999-06-24 Schering Corp Komposisi-komposisi yang berguna untuk tranferase protein farnesil
US5958890A (en) 1996-09-13 1999-09-28 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
US5861395A (en) 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
US5945429A (en) 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5965570A (en) 1996-09-13 1999-10-12 Schering Corporation Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
NZ337283A (en) 1997-02-18 2001-02-23 Canji Inc Use of a tumor suppressing nucleic acid which encodes wild type p53 or retinoblastoma proteins and paclitaxel derivative or a polyprenyl-protein transferase inhibitor for the treatment of neoplasms
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US5939416A (en) 1997-06-17 1999-08-17 Schering Corporation Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors
US5852034A (en) 1997-06-17 1998-12-22 Schering Corporation Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
US5925639A (en) 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US5877177A (en) 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5958940A (en) 1997-09-11 1999-09-28 Schering Corporation Tricyclic compounds useful as inhibitors of farnesyl-protein transferase
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JP2001526227A (ja) 1997-12-22 2001-12-18 シェーリング コーポレイション バイオアベイラビリティーを高めた分子分散組成物

Also Published As

Publication number Publication date
MY120841A (en) 2005-11-30
NZ514628A (en) 2004-01-30
US6316462B1 (en) 2001-11-13
EP1165078B1 (en) 2006-12-06
JP2003529540A (ja) 2003-10-07
NO329133B1 (no) 2010-08-30
BR0009670A (pt) 2002-01-15
HK1038512A1 (en) 2002-03-22
EP1165078A1 (en) 2002-01-02
DE60032226D1 (de) 2007-01-18
CN100421661C (zh) 2008-10-01
HUP0200773A3 (en) 2003-04-28
NO20014897L (no) 2001-12-10
ZA200108258B (en) 2003-03-26
AU783177B2 (en) 2005-09-29
PT1165078E (pt) 2007-02-28
CN1364084A (zh) 2002-08-14
AR023400A1 (es) 2002-09-04
CA2364675A1 (en) 2000-10-19
ES2275505T3 (es) 2007-06-16
DK1165078T3 (da) 2007-04-16
ATE347360T1 (de) 2006-12-15
MXPA01010211A (es) 2002-09-18
DE60032226T2 (de) 2007-10-11
CY1107545T1 (el) 2013-03-13
WO2000061145A1 (en) 2000-10-19
AU4204100A (en) 2000-11-14
HK1038512B (zh) 2007-04-27
TWI255184B (en) 2006-05-21
HUP0200773A2 (hu) 2002-07-29
NO20014897D0 (no) 2001-10-08

Similar Documents

Publication Publication Date Title
PE20010025A1 (es) Uso de un inhibidor de fpt y un inhibidor de la via de senalizacion ras adicional para inducir la muerte de celulas cancerosas y la regresion de tumores
BR0108394A (pt) Inibidores de cinase de proteìna de 2-indolinona de pirrol substituìdo
DE60143517D1 (de) Wiederherstellung der gelenken mit mesenchymalen stammzellen
BR0007527B1 (pt) fenilfenantridinas com atividade inibitària de pde-iv, seu uso, bem como medicamento compreendendo as mesmas.
PA8504401A1 (es) Compuestos farmaceuticamente activos
HN1998000143A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
SE7611379L (sv) Antihypertensiva medel
BR0207494A (pt) Derivados de 3-(4-amidopirrol-2-ilmetilideno)-2-indolinona como inibidores de proteìna quinase
EP1100870A4 (en) ENHANCING CARDIAC FUNCTIONING BY TRANSPLANTATION OF MESENCHYMAL STEM CELLS
CO5050288A1 (es) Derivados de 1,4-oxazolina y de 1,3-tiazolina, procedimiento y su utilizacion como agentes plaguicidas
ES2108125T3 (es) Aporte in vivo de factores activos por implantes de celulas cultivadas conjuntamente.
BRPI0107403B8 (pt) Compostos de n-(5,7-dimetóxi[1,2,4]triazolo[1,5-alfa]pirimidin-2-il) arilsulfonamida e o uso dos mesmos como herbicidas.
BR0316001A (pt) Derivados de pirimido[4,5-d]pirimidina com atividade anticâncer
TR200103460T2 (tr) 5-Fenil-pirimidin türevleri
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
DE60033918D1 (de) Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
DK1173439T3 (da) Halogenalkoxy-imidazonaphthyridiner
ATE294793T1 (de) Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
PE20000042A1 (es) Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativas
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
DE60025327D1 (de) 6-arylphenanthridine mit pde-iv hemmender wirkung
ATE402168T1 (de) Heterocyclische topoisomerase toxine
ATE290388T1 (de) Kombination von selen-haltigen verbindungen mit gemcitabin oder mitomycin c
ATE295352T1 (de) Phenanthridine-n-oxide mit pde-iv hemmender wirkung
AR044193A1 (es) Compuesto de 1,2,4-triazol-5-ona, composicion farmaceutica que lo comprende, su uso para prepararla y kit que comprende dicho compuesto

Legal Events

Date Code Title Description
FC Refusal